Giovanni Corso

@ieo.it

1. Breast Surgery, 2. Department of Oncology and Hemato-Oncology
1. European Institute of Oncology, 2. University of Milan, 3. European Cancer Prevention Organization (ECP)

Giovanni Corso


                                    Download Compact PDF  
https://researchid.co/giovanni.corso
Corso graduated MD cum laude at the University of Siena Italy in 2002. He specialized in general surgery in 2009, and received PhD in Medicine and Molecular Oncology at the University of Porto Corso has published about 160 international articles, 16 chapters and two books with Springer Science+Business Media.

EDUCATION

2012
PhD Gaduation in Medicine and Molecular Oncology with laude. University of Porto, Portugal.

2009
Specialization in General Surgery with laude. University of Siena, Italy.

2002
MD graduation with laude in Medicine and Surgery. University of Siena, Italy.

RESEARCH, TEACHING, or OTHER INTERESTS

Surgery, Genetics (clinical), Health Policy
220

Scopus Publications

9392

Scholar Citations

47

Scholar h-index

128

Scholar i10-index

Scopus Publications

  • Frequency of bilateral prophylactic and contra-lateral risk-reducing mastectomies in women with germline PALB2 variants
    Giovanni Corso, Carlo La Vecchia, Andrea Polizzi, Francesca Magnoni, Giuliarianna Abruzzese, et al.
    Familial Cancer, 2026
  • Invasive lobular and ductal breast cancers: a systematic review and metanalysis in association with BRCA1/2 mutation status
    Giovanni Corso, Chiara Andreon, Carlo La Vecchia, Elisa Ileana Bottazzoli, Giuliarianna Abruzzese, et al.
    European Journal of Cancer, 2026
  • Cancer mortality in Europe in 2020, and an overview of trends since 1990
    Claudia Santucci, Paola Bertuccio, Silvia Mignozzi, Margherita Pizzato, Giovanni Corso, et al.
    European Journal of Cancer Prevention, 2026
    Introduction Cancer remains a leading cause of death in Europe, with over 1.2 million deaths recorded in the EU-27 in 2020. Methods Using WHO death certification data for 33 European countries from 1990 to 2020, we analyzed mortality trends for all neoplasms and 24 cancer sites, stratified by sex and age. We computed age-standardized mortality rates (ASMR) and applied joinpoint regression models to evaluate temporal trends. Results In 2020, the leading causes of cancer death in the EU-27 were lung (ASMR: 30.1/100 000), colorectal (14.6/100 000), and prostate (9.8/100 000) cancer in males and breast (13.8/100 000), lung (13.2/100 000), and colorectal (8.6/100 000) cancer in females. Pancreatic cancer was the fourth most common cause of cancer death in both sexes (ASMR: 8.2/100 000 males and 5.8/100 000 females). Most Central and Eastern European countries reported rates over two-fold higher compared to Western Europe. While overall cancer mortality declined since 1990 (average annual percent change: −1.3% in males and −0.8% in females in the EU-27), mortality from pancreatic (+0.2% in males and +0.8% in females) and female lung cancer (+1.9%) increased. Conclusion Declines in cancer mortality are attributable to reduced tobacco use, and improvements in organized screening programs and treatment. Pancreatic cancer mortality remains stable, while female lung cancer mortality continues to rise in some countries, largely due to later adoption of smoking and low cessation rates. Lower participation in screening programs and limited access to novel therapies in many Central and Eastern European countries contribute to poorer cancer outcomes, highlighting the need for equitable prevention, early detection, and treatment strategies across Europe.
  • Long-term oncological outcomes of robotic mastectomy for breast cancer: a randomized clinical trial
    Antonio Toesca, Francesca Magnoni, Claudia Sangalli, Patrick Maisonneuve, Alessandra Gottardi, et al.
    British Journal of Surgery, 2026
  • Expectant management or conization for persistent low-grade cervical intraepithelial neoplasia: Analysis of 5-year outcomes
    Giorgio Bogani, Francesco Sopracordevole, Giovanni Corso, Enrico Vizza, Paolo Scollo, et al.
    Tumori, 2026
    Objective: To investigate to describe outcomes of conization or expectant management for women with persistent (>24 months) low-grade cervical intra-epithelial neoplasia. Methods: This is a retrospective analysis focusing on five-year outcomes after persistent, histologically confirmed, low-grade cervical intra-epithelial neoplasia undergoing conization or expectant management. Results: Charts of 219 women with persistent low-grade cervical lesions were retrieved. Overall, 98 (44.7%) and 121 (55.3%) women had conization and observation, respectively. Patients receiving conization were older than patients having observation (43 (range, 24-77) vs. 39 (range, 25-68) years; p=0.013). Focusing on the group of patients receiving conization, 16 (16.3%) women were diagnosed with CIN2+. The five-year risk of secondary conization was 5% (n=5). Focusing on patients having observation (n=121), 18 (14.8%) patients received conization, after a median of 16.5 (range, 6-30) months. Seven (5.8%) and 11 (9.1%) patients were diagnosed with persistent CIN1 and CIN2+, respectively. Not fully visible squamous-columnar junction at colposcopic examination (p=0.035) was associated with CIN2+ occurrence. No invasive cancer was observed Conclusions: Conization for persistent low-grade cervical intra-epithelial neoplasia revealed “occult” CIN2+ in 16% of patients. However, expectant management appears safe and effective in this context, in women with fully visible squamous columnar junction. The decision between conization and expectant management should be discussed on an individual basis.
  • Cancer mortality predictions for 2025 in Latin America with focus on prostate cancer
    Silvia Mignozzi, Claudia Santucci, Fabio Levi, Matteo Malvezzi, Paolo Boffetta, et al.
    European Journal of Cancer Prevention, 2026
    We provided cancer mortality rate estimates for the year 2025 in six Latin American countries (Argentina, Brazil, Chile, Colombia, Cuba, and Mexico), focusing on prostate cancer. We extracted mortality data for all cancers combined and the most common sites from the WHO and population data since 1970 from the United Nations. Estimates for 2025 were computed applying a linear regression to the most recent segment identified through Poisson join-point regression. Avoided deaths number from 1991 to 2025 was estimated by applying the 1990 peak rate to population data. Mortality from all cancers is predicted to be favorable for both sexes in all countries. The lowest total cancer mortality rates are expected in Mexico (67.7/100 000 males; 61.4/100 000 females), while the highest ones in Cuba (136.6/100 000 males; 91.6/100 000 females). Prostate cancer mortality is declining in all countries, although rates remain high in Cuba (25.2/100 000 in 2025). Downward patterns are observed for all age groups in all countries, except the elderly in Cuba and Mexico. Declines in mortality are predicted for colorectal (except for males in Brazil and Cuba, and females in Chile), stomach (except Cuban males), pancreatic (except Argentinian and Cuban males), lung, bladder (except Argentinian females), breast, and ovarian (except Cuba) cancers. Uterine cancer mortality, particularly from cervical cancer, remains highin Argentina (10.2/100 000) and Cuba (10.4/100 000). Except for uterine, stomach, and prostate cancers, cancer mortality rates are still relatively low in Latin America, except Cuba. Controlling tobacco particularly in Cuba, implementing organized cervical cancer screening, and advancing cancer treatment also for prostate cancer remain crucial in all countries considered.
  • The Algal Antioxidant Carotenoid Diatoxanthin as a Modulator of Inflammation and Angiogenesis in Triple-Negative Breast Cancer Cells
    Danilo Morelli, Luana Calabrone, Luisa Di Paola, Giovanna Chiorino, Paola Ostano, et al.
    Antioxidants, 2026
    Algal carotenoids play a promising role in handling chronic diseases due to their diverse bioactive properties, including anti-inflammatory, antioxidant, and anticancer effects. This study assesses the activity of the antioxidant xanthophyll diatoxanthin (Dt), derived from marine diatoms, against triple-negative breast cancer (TNBC) cells using in vitro models, gene expression evaluation, and explores its role in potentiating the cytotoxic effect of chemotherapy. Dt exhibited selective activity against MDA-MB-231 and BT-549 TNBC cells at concentrations ≥12.5 ng/mL, with maximal effects observed at 25 ng/mL while sparing human umbilical vein endothelial cells (HUVECs) at these doses. When combined with doxorubicin (0.1–0.5 μM), Dt enhanced the anti-tumor efficacy in both TNBC cell lines, further reducing cell viability compared with doxorubicin alone (p < 0.05–0.001). Dt also exerted its activity in inhibiting migration and chemotaxis by approximately 30–50% compared with the controls (p < 0.01) and suppressing 3D-tumor spheroid growth at day 12 (up to >50% reduction, p < 0.001). Notably, secretome analysis revealed Dt-induced changes in inflammatory, oxidative and angiogenic mediators, highlighting its ability to modulate the TNBC microenvironment. Dt also downregulated key pro-survival, pro-angiogenic and pro-tumorigenic genes in both TNBC cell lines, supporting its role in disrupting oncogenic pathways. Angiogenesis-related genes were significantly reduced. Dt also decreased the expression of angiogenic mediators in HUVECs, supporting Dt’s role in inhibiting tumor vascularization. Results on gene expression regulation were also confirmed by RNA-Seq analysis. These findings pose Dt as a promising chemopreventing candidate in the challenging fight against TNBC, a well-known type of cancer that is aggressive and resistant to conventional therapies, targeting critical pathways for tumor survival, such as inflammation, angiogenesis, tumor cell growth, and cell migration. Given its selective activity against TNBC cells, ability to enhance chemotherapy efficacy, and modulation of the tumor microenvironment, Dt holds promise as a complementary drug for cancer prevention and interception. Future studies should focus on validating these effects in vivo and exploring Dt’s potential in combinatorial treatment strategies for cancer.
  • Cancer as a main contributor to multimorbidity in the UK Biobank: analysis of risk factors using conventional statistical modelling and machine learning
    Linia Patel, Silvia Mignozzi, Margherita Pizzato, Giovanni Corso, Carlo La Vecchia, et al.
    European Journal of Cancer Prevention, 2026
    Cancer frequently co-occurs with other chronic conditions, contributing substantially to disease burden. Multimorbidity is an increasing public health concern, resulting from complex interactions between sociodemographic, lifestyle, and environmental factors. The study aimed to identify the main predictors of multimorbidity using both conventional statistical models and machine learning approaches. We analysed data from 138 126 UK Biobank participants aged 39–73 years. Twenty potential risk factors were assessed using Fine and Gray competing risk regression and random survival forests (RSF). Over the five-year follow-up period, 4384 individuals developed multimorbidity, with cancer present in 52.3% of cases. Five-year cumulative incidence was 3.9% in males and 2.6% in females. Increased waist circumference [males – hazard ratio: 1.15, 95% confidence interval (CI): 1.00–1.31; females – hazard ratio: 1.29, 95% CI: 1.09–1.54] and smoking (per 5 pack-years: males – hazard ratio: 1.06, 95% CI: 1.05–1.07; females – hazard ratio: 1.08, 95% CI: 1.06–1.10) significantly increased risk. Both insufficient and prolonged sleep were linked to a higher risk, especially among females (hazard ratio for prolonged sleep: 1.68, 95% CI: 1.17–2.40). Compared with moderate drinkers, former drinkers, lifelong abstainers, and heavy drinkers showed elevated risks. RSF found smoking, waist circumference, and sleep duration as key predictors in men, while alcohol use, smoking, and waist circumference were most important in women. Available dietary information, physical activity, and air pollution were not major predictors. Smoking, obesity, alcohol, and sleep duration are key risk factors to target in midlife to reduce the future burden of multimorbidity.
  • Cancer mortality predictions for 2026 in selected Asian countries and Australia with focus on prostate cancer
    Claudia Santucci, Silvia Mignozzi, Fabio Levi, Matteo Malvezzi, Giovanni Corso, et al.
    European Journal of Cancer Prevention, 2026
    Introduction We estimated cancer mortality figures for 2026 in five major Asian countries and Australia, with a specific focus on prostate cancer. Methods We computed country- and sex-specific annual age-standardized mortality rates (ASRs) for all cancers combined and for the 10 most common cancer sites, using data from the WHO and the United Nations Population Division up to 2022 or the most recent available year. We predicted figures for 2026 and estimated the number of avoided cancer deaths in 1994–2026. Results Predicted mortality rates for all cancers combined in 2026 are favourable across all considered countries and in both sexes, with the largest declines expected in the Republic of Korea (−20.5% in males and −10.2% in females compared with 2020–2022). In 2026, the lowest predicted male rate is expected in the Philippines (72.1 per 100 000), and the highest one in Australia (92.3 per 100 000). Among females, the lowest predicted ASR (42.2 per 100 000) is in the Republic of Korea, whereas the highest one (74.1 per 100 000) in the Philippines. Trends are generally favourable for lung, stomach, colorectum, and other major neoplasms considered, except pancreas. Predicted prostate cancer mortality is favourable in all countries and across all age groups. Rates are expected to remain low in Hong Kong SAR, Japan, and the Republic of Korea, with ASRs below 4 per 100 000 males. Since the 1993 observed peak rate, an estimated 132 000 total cancer deaths were avoided in Hong Kong SAR, 75 000 in Israel, 1 366 000 in Japan, 720 000 in the Republic of Korea, 328 000 in Australia, and 102 000 among men in the Philippines. Conclusions Declining cancer mortality is predicted in the countries considered. These trends largely reflect smoking cessation along with improvements in prevention, early detection, and treatment. However, substantial geographic disparities persist, highlighting the need for strengthened cancer control strategies, particularly in ageing populations.
  • Microcalcifications matter: Diagnostic and biological differences in DCIS
    Luca Nicosia, Luciano Mariano, Carmen Mallardi, Filippo Pesapane, Lorenza Meneghetti, et al.
    Cancer Treatment and Research Communications, 2026
  • Artificial intelligence for risk-stratified breast cancer screening: a systematic review of evidence, clinical integration, and ethical implications in risk assessment tools
    Filippo Pesapane, Francesca Caumo, Paola Mantellini, Giovanni Irmici, Catherine Depretto, et al.
    Radiologia Medica, 2026
  • Inflammation and cancer cell survival: TRAF2 as a key player
    Adriana Albini, Luisa Di Paola, Giampiero Mei, Denisa Baci, Nicola Fusco, et al.
    Cell Death and Disease, 2025
  • Sleep duration, selected circulating biomarkers, and colorectal cancer risk
    Marta Rossi, Alessia Pauletto, Silvia Mignozzi, Paola Bertuccio, Konstantinos K Tsilidis, et al.
    European Journal of Cancer Prevention, 2025
  • Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group
    Giovanni Corso, Sherry Shen, Carmen Criscitiello, Rita Mukhtar, Lauren Gamble, et al.
    Cancer Treatment Reviews, 2025
  • Cancer prevention and interception with antidiabetic and anti-obesity drugs: Current and future perspectives
    Adriana Albini, Anna Rita Cantelmo, Lorenzo Mortara, Douglas M. Noonan, Giovanni Corso
    Seminars in Cancer Biology, 2025
  • From Combination Early Detection to Multicancer Testing: Shifting Cancer Care toward Proactive Prevention and Interception
    Adriana Albini, Dario Trapani, Francesco Bertolini, Douglas M. Noonan, Roberto Orecchia, et al.
    Cancer Prevention Research, 2025
  • Diverging trends in lung cancer: a 26-year analysis of sex-specific patterns and histological shifts in Northern Italy
    Luca Bertolaccini, Claudia Santucci, Carlo La Vecchia, Federica Toffolutti, Giovanni Corso, et al.
    European Journal of Cancer Prevention, 2025
  • Second-hit CDH1 gene mechanisms in hereditary diffuse gastric and lobular breast cancer syndrome: frequency and impact on tumorigenesis
    Giovanni Corso, Francesca Magnoni, Matteo Dal Molin, Elena Marino, Luca Nicosia, et al.
    Human Molecular Genetics, 2025
  • Positive Margin Rates After Breast-Conserving Surgery by Histologic Subtype: A Systematic Review and Meta-analysis Evaluating the Impact of Oncoplastic Surgery
    Kayla M. Switalla, Israel O. Falade, Astrid Quirarte, Molly Baxter, Mandeep Kaur, et al.
    Annals of Surgical Oncology, 2025
  • Raising the bar: Evaluating quality and consistency in clinical guidelines for surgical management of pulmonary carcinoid
    Luca Bertolaccini, Claudia Bardoni, Giovanni Caffarena, Matteo Chiari, Cristina Diotti, et al.
    European Journal of Cancer Prevention, 2025
  • Preliminary Evaluation of Radiomics in Contrast-Enhanced Mammography for Prognostic Prediction of Breast Cancer
    Luca Nicosia, Luciano Mariano, Aurora Gaeta, Sara Raimondi, Filippo Pesapane, et al.
    Cancers, 2025
  • Invasive Pleomorphic Lobular Carcinoma of the breast: Clinicopathological features, treatment patterns and outcomes
    N Peradze, A Polizzi, E Pagan, E Bottazzoli, V Bagnardi, et al.
    European Journal of Surgical Oncology, 2025
  • Endometriosis and cancer risk
    Giorgio Bogani, Valentina Chiappa, Francesco Raspagliesi, Giovanni Corso
    European Journal of Cancer Prevention, 2025
  • Hereditary diffuse gastric and lobular breast cancer syndrome associated with germline CDH1 variants: focus on lobular breast cancer
    Giovanni Corso, Francesca Magnoni, Giorgio Bogani, Paolo Veronesi, Viviana Galimberti, et al.
    Journal of Cancer Research and Clinical Oncology, 2025
  • Malignant germ cells tumor of the ovary
    Francesca De Maria, Frédéric Amant, Valentina Chiappa, Biagio Paolini, Alice Bergamini, et al.
    Journal of Gynecologic Oncology, 2025

RECENT SCHOLAR PUBLICATIONS

  • Frequency of bilateral prophylactic and contra-lateral risk-reducing mastectomies in women with germline PALB2 variants
    G Corso, C La Vecchia, A Polizzi, F Magnoni, G Abruzzese, S Di Silvestre, ...
    Familial Cancer 25 (2), 40 , 2026
    2026
  • Artificial intelligence for risk-stratified breast cancer screening: a systematic review of evidence, clinical integration, and ethical implications in risk assessment tools
    F Pesapane, F Caumo, P Mantellini, G Irmici, C Depretto, S Penco, ...
    La radiologia medica, 1-22 , 2026
    2026
  • Cancer as a main contributor to multimorbidity in the UK Biobank: analysis of risk factors using conventional statistical modelling and machine learning
    L Patel, S Mignozzi, M Pizzato, G Corso, C La Vecchia, G Alicandro
    European Journal of Cancer Prevention 35 (3), 211-221 , 2026
    2026
  • Sleep duration, selected circulating biomarkers, and colorectal cancer risk
    M Rossi, A Pauletto, S Mignozzi, P Bertuccio, KK Tsilidis, M Mutignani, ...
    European Journal of Cancer Prevention 35 (3), 258-265 , 2026
    2026
    Citations: 1
  • Cancer mortality in Europe in 2020, and an overview of trends since 1990
    C Santucci, P Bertuccio, S Mignozzi, M Pizzato, G Corso, A Odone, ...
    European Journal of Cancer Prevention 35 (3), 193-210 , 2026
    2026
    Citations: 4
  • Adjuvant vaccination after conization for the treatment for cervical dysplasia
    C Caia, F De Maria, F Sopracordevole, A Ciavattini, J Casarin, F Ghezzi, ...
    European Journal of Cancer Prevention 35 (3), 243-249 , 2026
    2026
    Citations: 2
  • Long-term oncological outcomes of robotic mastectomy for breast cancer: a randomized clinical trial
    A Toesca, F Magnoni, C Sangalli, P Maisonneuve, A Gottardi, ...
    British Journal of Surgery 113 (4), znag007 , 2026
    2026
  • Invasive lobular and ductal breast cancers: a systematic review and metanalysis in association with BRCA1/2 mutation status
    G Corso, C Andreon, C La Vecchia, EI Bottazzoli, G Abruzzese, K Favilla, ...
    European Journal of Cancer, 116692 , 2026
    2026
    Citations: 1
  • Cancer mortality predictions for 2025 in Latin America with focus on prostate cancer
    S Mignozzi, C Santucci, F Levi, M Malvezzi, P Boffetta, G Corso, E Negri, ...
    European Journal of Cancer Prevention 35 (2), 97-107 , 2026
    2026
    Citations: 5
  • Microcalcifications Matter: Diagnostic and Biological Differences in DCIS
    L Nicosia, L Mariano, C Mallardi, F Pesapane, L Meneghetti, F Abbate, ...
    Cancer Treatment and Research Communications, 101135 , 2026
    2026
  • Expectant management or conization for persistent low-grade cervical intraepithelial neoplasia: Analysis of 5-year outcomes
    G Bogani, F Sopracordevole, G Corso, E Vizza, P Scollo, A Giannini, ...
    Tumori Journal 112 (1), 75-82 , 2026
    2026
    Citations: 2
  • Cancer mortality predictions for 2026 in selected Asian countries and Australia with focus on prostate cancer
    C Santucci, S Mignozzi, F Levi, M Malvezzi, G Corso, E Negri, ...
    European Journal of Cancer Prevention, 10.1097 , 2026
    2026
  • Anthropometric factors, physical activity, and the risk of soft tissue sarcoma: a case–control study
    F Turati, G Esposito, M Pizzato, P Bertuccio, C Galeone, C Santucci, ...
    European Journal of Cancer Prevention, 10.1097 , 2026
    2026
  • The global burden of kidney cancer: trends in mortality and incidence with predictions to 2025
    S Mignozzi, C Santucci, A Briganti, F Montorsi, C La Vecchia, G Corso, ...
    European Journal of Cancer Prevention, 10.1097 , 2025
    2025
    Citations: 2
  • Microplastics and cancer
    G Bogani, E Trimarchi, V Chiappa, G Vizzielli, F Raspagliesi, ...
    European Journal of Cancer Prevention, 10.1097 , 2025
    2025
    Citations: 1
  • From combination early detection to multicancer testing: shifting cancer care toward proactive prevention and interception
    A Albini, D Trapani, F Bertolini, DM Noonan, R Orecchia, G Corso
    Cancer Prevention Research 18 (10), 583-602 , 2025
    2025
    Citations: 2
  • The URBioPark Project: Bridging Biodiversity, Urban Public Spaces Quality and Public Health
    M Tiboni, A Bertolazzi, M Nota, A Amatucci, P Carletti, GD Corso, ...
    International Conference Living and Walking in Cities, 389-401 , 2025
    2025
  • ASO Visual Abstract: Positive Margin Rates After Breast-Conserving Surgery by Histologic Subtype: A Systematic Review and Meta-Analysis Evaluating the Impact of Oncoplastic Surgery
    KM Switalla, IO Falade, A Quirarte, M Baxter, M Kaur, RA Sakr, G Corso, ...
    Annals of surgical oncology , 2025
    2025
  • Diverging trends in lung cancer: a 26-year analysis of sex-specific patterns and histological shifts in Northern Italy
    L Bertolaccini, C Santucci, C La Vecchia, F Toffolutti, G Corso, L Spaggiari, ...
    European Journal of Cancer Prevention 34 (5), 475-482 , 2025
    2025
  • Second-hit CDH1 gene mechanisms in hereditary diffuse gastric and lobular breast cancer syndrome: frequency and impact on tumorigenesis
    G Corso, F Magnoni, M Dal Molin, E Marino, L Nicosia, F Pesapane, ...
    Human molecular genetics 34 (16), 1345-1352 , 2025
    2025
    Citations: 8

MOST CITED SCHOLAR PUBLICATIONS

  • Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond
    S Hansford, P Kaurah, H Li-Chang, M Woo, J Senz, H Pinheiro, ...
    JAMA oncology 1 (1), 23-32 , 2015
    2015
    Citations: 876
  • Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized …
    OD Gentilini, E Botteri, C Sangalli, V Galimberti, M Porpiglia, R Agresti, ...
    JAMA oncology 9 (11), 1557-1564 , 2023
    2023
    Citations: 617
  • Profiling critical cancer gene mutations in clinical tumor samples
    LE MacConaill, CD Campbell, SM Kehoe, AJ Bass, C Hatton, L Niu, ...
    PloS one 4 (11), e7887 , 2009
    2009
    Citations: 379
  • Nipple-sparing and skin-sparing mastectomy: review of aims, oncological safety and contraindications
    V Galimberti, E Vicini, G Corso, C Morigi, S Fontana, V Sacchini, ...
    The Breast 34, S82-S84 , 2017
    2017
    Citations: 369
  • Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis
    AM Dulak, SE Schumacher, J Van Lieshout, Y Imamura, C Fox, B Shim, ...
    Cancer research 72 (17), 4383-4393 , 2012
    2012
    Citations: 336
  • Number of lymph node metastases and its prognostic significance in early gastric cancer: a multicenter Italian study
    F Roviello, S Rossi, D Marrelli, C Pedrazzani, G Corso, C Vindigni, ...
    Journal of surgical oncology 94 (4), 275-280 , 2006
    2006
    Citations: 309
  • Germline CDH1 deletions in hereditary diffuse gastric cancer families
    C Oliveira, J Senz, P Kaurah, H Pinheiro, R Sanges, A Haegert, G Corso, ...
    Human molecular genetics 18 (9), 1545-1555 , 2009
    2009
    Citations: 283
  • Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer
    G Corso, J Carvalho, D Marrelli, C Vindigni, B Carvalho, R Seruca, ...
    Journal of clinical oncology 31 (7), 868-875 , 2013
    2013
    Citations: 230
  • Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up
    S Kahler-Ribeiro-Fontana, E Pagan, F Magnoni, E Vicini, C Morigi, ...
    European Journal of Surgical Oncology 47 (4), 804-812 , 2021
    2021
    Citations: 210
  • CDH1 germline mutations and hereditary lobular breast cancer
    G Corso, M Intra, C Trentin, P Veronesi, V Galimberti
    Familial Cancer 15 (2), 215-219 , 2016
    2016
    Citations: 166
  • E‐cadherin deregulation in breast cancer
    G Corso, J Figueiredo, SP De Angelis, F Corso, A Girardi, J Pereira, ...
    Journal of cellular and molecular medicine 24 (11), 5930-5936 , 2020
    2020
    Citations: 165
  • Perforated gastric carcinoma: a report of 10 cases and review of the literature
    F Roviello, S Rossi, D Marrelli, G De Manzoni, C Pedrazzani, P Morgagni, ...
    World Journal of Surgical Oncology 4 (1), 19 , 2006
    2006
    Citations: 163
  • Axillary surgery in breast cancer: An updated historical perspective
    F Magnoni, V Galimberti, G Corso, M Intra, V Sacchini, P Veronesi
    Seminars in oncology 47 (6), 341-352 , 2020
    2020
    Citations: 152
  • Lymph node involvement in advanced gastroesophageal junction adenocarcinoma
    C Pedrazzani, G De Manzoni, D Marrelli, S Giacopuzzi, G Corso, ...
    The Journal of Thoracic and Cardiovascular Surgery 134 (2), 378-385 , 2007
    2007
    Citations: 139
  • Oncogenic mutations in gastric cancer with microsatellite instability
    G Corso, S Velho, J Paredes, C Pedrazzani, D Martins, F Milanezi, ...
    European Journal of Cancer 47 (3), 443-451 , 2011
    2011
    Citations: 137
  • Frequency of CDH1 germline mutations in gastric carcinoma coming from high- and low-risk areas: metanalysis and systematic review of the literature
    G Corso, D Marrelli, V Pascale, C Vindigni, F Roviello
    BMC cancer 12 (1), 8 , 2012
    2012
    Citations: 136
  • Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer
    M Kalimutho, S Di Cecilia, G Del Vecchio Blanco, F Roviello, P Sileri, ...
    British journal of cancer 104 (11), 1770-1778 , 2011
    2011
    Citations: 128
  • Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer
    D Marrelli, C Pedrazzani, A Berardi, G Corso, A Neri, L Garosi, C Vindigni, ...
    Cancer 115 (10), 2071-2080 , 2009
    2009
    Citations: 125
  • Complications after Extended (D2) and Superextended (D3) Lymphadenectomy for Gastric Cancer: Analysis of Potential Risk Factors: D. MARRELLI ET AL.
    D Marrelli, C Pedrazzani, A Neri, G Corso, A De Stefano, E Pinto, ...
    Annals of surgical oncology 14 (1), 25-33 , 2007
    2007
    Citations: 124
  • A randomized trial of robotic mastectomy versus open surgery in women with breast cancer or BrCA mutation
    A Toesca, C Sangalli, P Maisonneuve, G Massari, A Girardi, JL Baker, ...
    Annals of surgery 276 (1), 11-19 , 2022
    2022
    Citations: 123